POSITION PAPER
Inequity of care and limited access to affordable treatment for patients with Alpha 1- Antitrypsin Deficiency are global health issues and exacerbate chronic illness iN Alpha-1 patients where treatment access is an issue.
BROCHURE: ALPHA-1 DEEP DIVE
This brochure contains information about the genetic disorder known as alpha-1 antitrypsin deficiency (A1AD). A1AD is a disorder, not a disease, but can cause disease in some people.
FACT SHEET: PANNICULITIS
Panniculitis is a very rare but treatable condition, sometimes related to A1AD. Its estimated prevalence is one in 1,000 patients with the Pi*ZZ A1AD genotype.
BROCHURE: A1AD OVERVIEW
A1AD is a common genetic (inherited) disorder associated with low levels of a natural protein known as Alpha-1 Antitrypsin (AAT). Low levels of AAT can cause a number of diseases.
BROCHURE: A1AD HEALTH ISSUES
A1AD is a complicated and sometimes challenging diagnosis. Not everyone with abnormal Alpha-1 Antitrypsin Deficiency (AAT) is affected by the deficiency.
BROCHURE: QUESTIONS for YOUR Dr.
You are likely to have a lot of questions following a diagnosis of Alpha-1 Antitrypsin Deficiency (A1AD). Select the questions in the attachment that best relate to you.
FACT SHEET: AUGMENTATION THERAPY
There is only one treatment available to protect the lungs of people with A1AD. The treatment is Alpha-1 proteinase inhibitor (also called Augmentation Therapy).
POSITION PAPER: GAYNOR HEADING Phd
A position paper from Gaynor Heading PhD (Med), President of Alpha-1 Organisation Australia, focusing on preventing harm and saving lives for individuals with A1AD.
FACT SHEET: HOME OXYGEN THERAPY
There are several types of devices that provide medical grade oxygen, all of which provide oxygen to the lungs via tubing and mask / cannula or similar facial device.